diabetes

ACC 2024

ACC 2024 | DEDICATE Trial: Transcatheter or Surgical Treatment of Aortic Valve Stenosis

In recent years, TAVR has been increasingly used; however, when it comes to younger, lower risk patients, its use is still challenged.&nbsp; In this context, there is limited information and we lack randomized studies on “real world” cohorts.&nbsp; The DEDICATE randomized 1.414 patients over 65 with severe symptomatic aortic stenosis. 701 of these patients received<a href="https://solaci.org/en/2024/04/11/acc-2024-dedicate-trial-transcatheter-or-surgical-treatment-of-aortic-valve-stenosis/" title="Read more" >...</a>

ACC 2024

ACC 2024 | ULTIMATE-DAPT Trial

The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor during 12 months in patients receiving percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), to prevent events such as MI and stent thrombosis.&nbsp; This was a multicenter, placebo controlled, double blind study to determine whether ticagrelor alone,<a href="https://solaci.org/en/2024/04/10/acc-2024-ultimate-dapt-trial/" title="Read more" >...</a>

ACC 2024

ACC 2024 | RELIEVE-HF

Heart failure is characterized by increased left atrial filling pressure and venous congestion which intensify with exercise and volume burden, and makes conventional medical management hard. In this context, interatrial shunting might offer a self-regulating mechanism, as shown by the Ventura IAS study. The aim of this study was to assess the safety and efficacy<a href="https://solaci.org/en/2024/04/10/acc-2024-relieve-hf/" title="Read more" >...</a>

Lithotripsy in the “Real World”: REPLICA EPIC-18 Study

Severe persistent calcification of the coronary arteries has been associated with different factors, such as advanced age, hypertension, dyslipidemia, smoking, and kidney failure, among others, and continues to be one of the challenges to stent implantation because of it impact on device advancing, drug release and adequate positioning.&nbsp; Intravascular lithotripsy (IVL) is a technique that<a href="https://solaci.org/en/2024/04/05/lithotripsy-in-the-real-world-replica-epic-18-study/" title="Read more" >...</a>

¿Es seguro utilizar iFR para diferir lesiones del tronco de la coronaria izquierda?

Rehospitalization After Treatment of Left Main Coronary Artery Disease and Its Prognosis: Sub-Analysis of the EXCEL Study

Individual randomized studies have shown variable results regarding the mortality risk following treatment of left main coronary artery disease (LMCAD), either through percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). However, upon assessment of the latest meta-analyses (with matched data), similar risks of all-cause and cardiovascular mortality have been reported for both groups.<a href="https://solaci.org/en/2024/03/21/rehospitalization-after-treatment-of-left-main-coronary-artery-disease-and-its-prognosis-sub-analysis-of-the-excel-study/" title="Read more" >...</a>

Subutilización del tratamiento médico en enfermedad vascular periférica

ISCHEMIA Outcomes: Does Sex Have Any Impact?

We are well aware of CAD physiopathological disparities and how it manifests differently in men and women. The ISCHEMIA study (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) has revealed that during 3.2 years no differences were seen in the incidence of ischemic events when comparing an invasive strategy (INV) vs a<a href="https://solaci.org/en/2024/03/20/ischemia-outcomes-does-sex-have-any-impact/" title="Read more" >...</a>

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

TENDER Study, Evolution at One Year

The use of transcatheter mitral valve intervention for the treatment of mitral valve regurgitation (MR) continues to evolve; at present guidelines only recommend it for inoperable or high surgical risk patients.&nbsp;&nbsp;&nbsp; So far, many devices have been assessed, some of which have shown promising results, but only for poor surgical candidates.&nbsp; Researchers looked into the<a href="https://solaci.org/en/2024/03/15/tender-study-evolution-at-one-year/" title="Read more" >...</a>

Se publicaron los resultados del estudio RESPECT con excelentes novedades

Lithotripsy in the Left Main Coronary Artery

A lesion ≥50% in the left main coronary artery (LMCA) is considered severe, according to various scientific societies, regardless of the presence of symptoms or ischemia, due to the extent of myocardium at risk. In such cases, revascularization is indicated. In many patients, lesions in this section of the coronary artery have severe calcification, which<a href="https://solaci.org/en/2024/03/13/lithotripsy-in-the-left-main-coronary-artery/" title="Read more" >...</a>

Resultados a 2 años de los stents liberadores de Zotarolimus vs stents libres de polímero liberadores de Biolimus. ¿Son seguros en pacientes con alto riesgo de sangrado?

IN.PACT Outcomes at 5 Years

Over time, percutaneous coronary intervention (PCI) with drug coated balloons (DCB) have been shown more beneficial than conventional PCI. However, in many cases, stenting is required to treat suboptimal results.&nbsp; Even though several studies have looked into this scenario, long term durability still calls for research. This was a 5 year thorough analysis of the<a href="https://solaci.org/en/2024/03/09/in-pact-outcomes-at-5-years/" title="Read more" >...</a>

POKI: una nueva estrategia en bifurcaciones

Proximal Optimization Technique in Unprotected LMCA

Proximal optimization technique (POT) has been recommended as a standard strategy in bifurcation lesions because it facilitates proper stent implantation and apposition in the proximal main vessel, according to the European Bifurcation Club. Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery (LMCA) has specific characteristics, and the long-term impact of this strategy<a href="https://solaci.org/en/2024/03/06/proximal-optimization-technique-in-unprotected-lmca/" title="Read more" >...</a>

Top